Gopa Iyer, MD
Genitourinary Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Section Head, Bladder Cancer
I am a medical oncologist who specializes in research in and treatment of patients with genitourinary cancers, including bladder, prostate, kidney, and testis cancers.
I also have a special interest in understanding the genetic basis for bladder cancer and am a member of Memorial Sloan Kettering’s Bladder Cancer Oncogenome Project, a multidisciplinary effort to discover the key genetic abnormailities that drive this disease. The discovery and understanding of these genetic abnormalities hold the promise of novel treatments for patients with bladder cancer.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Bladder Cancer
- Other Genitourinary Malignancies
Education
- MD, Vanderbilt University School of Medicine
Residencies
- Internal Medicine - University of Michigan
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Iyer sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Iyer
- A Phase 1 Study of TYRA-300 in People with Advanced Bladder Cancer
- A Phase 1a Study of LOXO-435 in People with Advanced Solid Tumors Containing FGFR3 Gene Changes
- A Phase 2 Study of Disitamab Vedotin Alone and with Pembrolizumab Immunotherapy in People with Inoperable or Metastatic Urothelial Cancer
- A Phase 2 Study of Enfortumab Vedotin in People with Urothelial Cancer of the Upper Urinary Tract
Read more
- A Phase II Study of Chemotherapy without Surgery in Patients with Muscle-Invasive Bladder Cancer and Certain Gene Mutations
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy
- Clinical Trials Co-Investigated by Dr. Iyer
- A Phase 1 Study of TNG908 in People with Sarcoma, Mesothelioma, or Glioblastoma
- A Phase 1a Study of LY4101174 in People With Bladder or Prostate Cancer
- A Phase 2 Study of Datopotamab Deruxtecan Alone or With Other Anti-Cancer Drugs in People Endometrial, Ovarian, and Urothelial Cancers
- A Phase 2/3 Study Assessing Tumor DNA in the Blood to Guide the Use of Immunotherapy After Bladder Cancer Surgery
- A Phase I Study of ADP-A2M4CD8 with or without Nivolumab Immunotherapy in People with Urothelial Cancer, Non-Small Cell Lung Cancer, or Endometrial Cancer
- A Phase II Study of Ado-Trastuzumab Emtansine in Patients with Cancers Driven by HER2
- A Phase II Study of Oral Erdafitinib in People with Recurrent Non-Invasive Bladder Cancer
- A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Iyer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gopa Iyer discloses the following relationships and financial interests:
-
Aadi Bioscience, Inc.
Professional Services and Activities -
Bicycle Therapeutics Inc.
Professional Services and Activities -
Carden Jennings Publishing
Professional Services and Activities -
Curio Science LLC
Professional Services and Activities
-
Dava Oncology
Professional Services and Activities (Uncompensated) -
EMD Serono, Inc
Professional Services and Activities -
Flare Therapeutics
Professional Services and Activities (Uncompensated) -
Loxo Oncology
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].